A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Status: Active_not_recruiting
Location: See all (72) locations...
Intervention Type: Biological, Other, Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
• At least 1 lesion accessible for biopsy
• Eastern Cooperative Oncology Group Performance Status of 0 or 1
Locations
United States
Arkansas
Local Institution - 0059
Springdale
California
Local Institution - 0099
Los Angeles
Colorado
Local Institution - 0007
Lakewood
Georgia
Local Institution - 0087
Atlanta
Local Institution - 0100
Atlanta
Local Institution - 0101
Marietta
Massachusetts
Local Institution - 0060
Boston
Maryland
Local Institution - 0012
Columbia
Local Institution - 0003
Lutherville
Michigan
Local Institution - 0004
Ann Arbor
Nebraska
Local Institution - 0076
Omaha
New Jersey
Local Institution - 0005
Hackensack
Local Institution - 0032
New Brunswick
Nevada
Comprehensive Cancer Centers Of Nevada
Las Vegas
New York
Local Institution - 0002
New York
Local Institution - 0025
New York
Oklahoma
Local Institution - 0028
Oklahoma City
Oregon
Local Institution - 0017
Eugene
Pennsylvania
Local Institution - 0001
Pittsburgh
South Carolina
Local Institution - 0009
Greenville
Texas
Local Institution - 0011
Austin
Local Institution - 0010
Dallas
Local Institution - 0014
Fort Worth
Local Institution - 0018
Houston
Local Institution - 0006
San Antonio
Local Institution - 0013
Tyler
Utah
Local Institution - 0058
Salt Lake City
Virginia
Local Institution - 0015
Fairfax
Local Institution - 0008
Norfolk
Other Locations
Australia
Local Institution - 0096
Adelaide
Local Institution - 0091
Ballarat Central
Local Institution - 0090
Melbourne
Local Institution - 0095
Melbourne
Local Institution - 0097
Perth
Local Institution - 0088
Wollstonecraft
Belgium
Local Institution - 0037
Brussels
Local Institution - 0036
Ghent
Local Institution - 0082
Kortrijk
Canada
Local Institution - 0030
Edmonton
Local Institution - 0056
Montreal
Local Institution - 0020
Toronto
Local Institution - 0055
Toronto
Local Institution - 0029
Vancouver
Local Institution - 0078
Victoria
France
Local Institution - 0067
Marseille
Local Institution - 0085
Nantes
Local Institution - 0068
Paris
Local Institution - 0102
Toulouse
Local Institution - 0069
Villejuif
Germany
Local Institution - 0034
Berlin
Local Institution - 0053
Hamburg
Local Institution - 0052
Mainz
Local Institution - 0054
Tübingen
Italy
Local Institution - 0043
Forlì
Local Institution - 0042
Milan
Local Institution - 0027
Napoli
Local Institution - 0026
Rozzano-milano
Poland
Local Institution - 0071
Krakow
Local Institution - 0077
Warsaw
Spain
Local Institution - 0022
Madrid
Local Institution - 0023
Madrid
Local Institution - 0045
Madrid
Local Institution - 0044
Málaga
Local Institution - 0021
Pamplona
Local Institution - 0047
Santiago De Compostela
Sweden
Local Institution - 0049
Lund
Switzerland
Local Institution - 0040
Lausanne
Local Institution - 0041
Sankt Gallen
Local Institution - 0039
Zurich
United Kingdom
Local Institution - 0019
Birmingham
Local Institution - 0083
Glasgow
Local Institution - 0024
Manchester
Time Frame
Start Date: 2018-02-12
Completion Date: 2025-11-30
Participants
Target number of participants: 281
Treatments
Experimental: Part 1A: BMS-986253 + nivolumab
Experimental: Part 1B: BMS-986253 + nivolumab
Experimental: Part 1C: BMS-986253 + nivolumab + ipilimumab
Experimental: Part 2A: BMS-986253 + nivolumab + ipilimumab
Placebo_comparator: Part 2B: Placebo + nivolumab + ipilimumab
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb